Understanding genetic variants in lung adenocarcinoma among Mexican patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prevalence of germline pathogenic variants in Mexican patients diagnosed with lung adenocarcinoma, particularly focusing on those under fifty years of age. It will explore the clinical-pathological characteristics associated with these variants and investigate the relationship between actionable somatic mutations and germline variants. Participants will provide a blood sample for DNA extraction and next-generation sequencing to identify genetic alterations. The study is designed to gather comprehensive data that could enhance understanding of lung adenocarcinoma genetics in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Both sexes
* ≥ 16 years old, according the institutional protocols for new patients admittances.
* histologically confirmed lung adenocarcinoma (LUAD)
* Signed written informed consent form
* A life expectancy greater than 8 weeks.
* Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET).

Exclusion Criteria:

* A sample of peripheral blood that is not accessible.
* Insufficient clinical pathological information in the electronic clinical record.

Elimination Criteria:

* Withdrawal
* Insufficient DNA quality and quantity for genomic sequencing analyses.
* Lost of follow up

Where it's running

• Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
  Mexico City, Mexico City, Mexico Recruiting

Study contacts

• Principal investigator: Oscar G Arrieta Rodriguez, M.D., M.Sc. — Instituto Nacional de Cancerologia de Mexico
• Study coordinator: Oscar G Arrieta Rodriguez, M.D., M.Sc.
• Email: ogar@unam.mx
• Phone: 5556280400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions

  This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.

  Recruiting Sheba Medical Center · Ramat Gan, Israel · NCT07636252

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• 7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma

  This trial will test whether a personalized 7-day ketogenic (low-carb, high-fat) diet before an FDG PET/CT can improve detection of lepidic-predominant lung adenocarcinoma in adults with a suspicious lung nodule or confirmed diagnosis.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Torino (TO) · NCT07479095

• Partial high-dose tumor irradiation combined with immunotherapy for unresectable lung adenocarcinoma

  This trial will try giving very high-dose radiation to the central part of large, unresectable lung adenocarcinomas while preserving the surrounding immune tissue and pairing that with an immune checkpoint drug for patients who have no remaining standard treatment options.

  Recruiting Karl Landsteiner University of Health Sciences · Krems, Austria · NCT07423169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.